Basel Medical Group (NASDAQ:BMGL) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Basel Medical Group (NASDAQ:BMGL – Free Report) to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings cut Basel Medical Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has an average rating of “Sell”.

Get Our Latest Stock Report on Basel Medical Group

Basel Medical Group Stock Up 2.1%

Basel Medical Group stock opened at $5.40 on Friday. Basel Medical Group has a 12-month low of $2.56 and a 12-month high of $18.48. The firm’s fifty day moving average price is $4.37 and its 200 day moving average price is $6.38.

Basel Medical Group (NASDAQ:BMGL – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported ($0.31) EPS for the quarter. The company had revenue of $3.14 million during the quarter.

About Basel Medical Group

(Get Free Report)

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.

Further Reading